Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Antoine Robinson"'
Publikováno v:
Annals of Noninvasive Electrocardiology. 19:582-594
Background Guanfacine (Intuniv) is a centrally active alpha-2A adrenergic agonist for the new indication of attention-deficit/hyperactivity disorder. QTc (QTcF and QTcNi) was prolonged at both therapeutic (4 mg) and supratherapeutic (8 mg) doses of a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7f394d6acad00ee267dd798fe5b9b282
https://doi.org/10.1111/anec.12202
https://doi.org/10.1111/anec.12202
The effect of sevelamer carbonate and lanthanum carbonate on the pharmacokinetics of oral calcitriol
Autor:
Antoine Robinson, Michael Smyth, Lynne Poole, Heather Van Heusen, Patrick Martin, David M. Pierce, Stuart Hossack
Publikováno v:
Nephrology Dialysis Transplantation
Background. Lanthanum carbonate and sevelamer carbonate are non-calcium-based phosphate binders used to manage hyperphosphataemia in patients with chronic kidney disease (CKD). Patients with CKD may require intravenous or oral active vitamin D. We in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9516150c77bae03279896123e233df16
https://doi.org/10.1093/ndt/gfq598
https://doi.org/10.1093/ndt/gfq598
Publikováno v:
Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc. 19(6)
BACKGROUND: Guanfacine (Intuniv) is a centrally active alpha‐2A adrenergic agonist for the new indication of attention‐deficit/hyperactivity disorder. QTc (QTcF and QTcNi) was prolonged at both therapeutic (4 mg) and supratherapeutic (8 mg) doses
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::64fd22e32abc224f1546165c84566190
https://pubmed.ncbi.nlm.nih.gov/25200912
https://pubmed.ncbi.nlm.nih.gov/25200912
Autor:
Antoine Robinson, Robert S. Kahn, Jaideep Purkayastha, Lawrence Satin, James Ermer, Patrick Martin, Mary Corcoran, Sharon H. Youcha
Publikováno v:
Int. Journal of Clinical Pharmacology and Therapeutics.
Objectives: Guanfacine ex- tended-release (GXR) is approved for the treatment of attention-deficit/hyperactiv- ity disorder in children and adolescents. As part of the clinical development of GXR, and to further explore the effect of guanfa- cine on
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::097c4cae55441ff5ceb85f64d1b45a9c
https://doi.org/10.5414/cp202065
https://doi.org/10.5414/cp202065
Publikováno v:
Clinical therapeutics. 34(6)
Background Phosphate binders are commonly used in tablet form to help patients with hyperphosphatemia limit their absorption of dietary phosphate. These patients frequently have a heavy tablet burden so alternative formulations provide choice and may
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b869fb135d7c1161c1268d75d7e6f09e
https://pubmed.ncbi.nlm.nih.gov/22657252
https://pubmed.ncbi.nlm.nih.gov/22657252
Autor:
Raymond D. Pratt, Antoine Robinson, Lynne Poole, Patrick Martin, Phillip Wang, Jeffrey Dragone, Michael Smyth
Publikováno v:
American journal of kidney diseases : the official journal of the National Kidney Foundation. 57(5)
Lanthanum carbonate and sevelamer carbonate are noncalcium phosphate binders used to treat hyperphosphatemia in patients with chronic kidney disease. This is the first study to compare phosphate absorption from a standardized meal ingested with a typ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0fd0899b465f82503ee27b902d5e4125
https://pubmed.ncbi.nlm.nih.gov/21354682
https://pubmed.ncbi.nlm.nih.gov/21354682
Publikováno v:
Clinical Autonomic Research
Objective Midodrine hydrochloride is a short-acting pressor agent that raises blood pressure in the upright position in patients with orthostatic hypotension. The US Food and Drug Administration’s Subpart H approval, under which midodrine was initi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::762acd48e4e98565a358a75959f5b7c0